Legatum CEO, Mark Stoleson, explains how the firm first tested the effectiveness of treatments during a lengthy pilot scheme before realising that, by simply addressing the tropical diseases with low-cost measures, the treatments could have a positive impact on the lives of millions.
Mark Stoleson, CEO and Partner of Legatum, is quoted in this article as saying that the firm wants to help others and only invests their own money.